Fluctuations in NRF2 levels predict the chemotherapy response and survival outcomes of NSCLC patients receiving neoadjuvant chemotherapy, and unaltered NRF2 expression correlates with poor survival rates and chemotherapy resistance in NSCLC patients [98]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.